 Stealth BioTherapeutics Corp Nasdaq:MITO, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has completed a 20 million private placement with Morningside Venture I Investments Limited Morningside. As part of the financing, Morningside purchased 152,858,460 ordinary shares at a price of US 0.13084 per ordinary share. The last reported closing price of the Companys American Depositary Shares ADS on Nasdaq was 1.57; each ADS represents 12 ordinary shares. 